NEWARK, Del.--(BUSINESS WIRE)--Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today it has received approval from the Food and Drug Administration to proceed with the first human clinical trial of plant-produced H5N1 influenza vaccine.